tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Ventricular Dysfunction, Left D018487 33 associated lipids
Hyperparathyroidism, Secondary D006962 4 associated lipids
Neuritis D009443 4 associated lipids
Hypertension, Portal D006975 12 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Hepatitis C D006526 7 associated lipids
Lichen Planus D008010 3 associated lipids
Sclerosis D012598 5 associated lipids
Atherosclerosis D050197 85 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Insulin Resistance D007333 99 associated lipids
Liver Failure, Acute D017114 11 associated lipids
Diabetes Complications D048909 4 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Dental Pulp Calcification D003784 2 associated lipids
Hepatitis C, Chronic D019698 12 associated lipids
Coronary Stenosis D023921 6 associated lipids
Dehydration D003681 11 associated lipids
Hemophilia A D006467 10 associated lipids
Encephalitis D004660 15 associated lipids
Dyslipidemias D050171 7 associated lipids
Fatigue D005221 10 associated lipids
Meningoencephalitis D008590 4 associated lipids
Gynecomastia D006177 6 associated lipids
Thyroiditis, Autoimmune D013967 9 associated lipids
Myxedema D009230 2 associated lipids
Pregnancy Complications D011248 19 associated lipids
Candidiasis, Oral D002180 11 associated lipids
Stomatitis D013280 14 associated lipids
Biliary Tract Neoplasms D001661 7 associated lipids
Lung Diseases, Interstitial D017563 5 associated lipids
Weight Loss D015431 56 associated lipids
Tinea D014005 5 associated lipids
Critical Illness D016638 13 associated lipids
Endotoxemia D019446 27 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Memory Disorders D008569 33 associated lipids
Glucose Intolerance D018149 13 associated lipids
Dry Eye Syndromes D015352 10 associated lipids
Thinness D013851 11 associated lipids
Opportunistic Infections D009894 8 associated lipids
Eczema D004485 4 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Vasculitis, Leukocytoclastic, Cutaneous D018366 5 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Lupus Nephritis D008181 8 associated lipids
Telangiectasis D013684 2 associated lipids
Anemia, Iron-Deficiency D018798 6 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Sawabe T et al. Sinus arrest during tacrolimus (FK506) and digitalis treatment in a bone marrow transplant recipient. 1997 Transplantation pmid:9233725
Silva HT et al. Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients. 2014 Transplantation pmid:24521771
Heeckt PF et al. Functional impairment of enteric smooth muscle and nerves caused by chronic intestinal allograft rejection regresses after FK506 rescue. 1995 Transplantation pmid:7530870
Gruessner RW et al. A prospective study of FK506 versus CsA and pig ATG in a porcine model of small bowel transplantation. 1995 Transplantation pmid:7530871
Jindal RM et al. Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporine versus FK506. 1994 Transplantation pmid:7514317
Eason JD et al. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. 2003 Transplantation pmid:12717237
Pescovitz MD et al. Prospective observational study of sirolimus as primary immunosuppression after renal transplantation. 2009 Transplantation pmid:19855247
Drachenberg CB et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. 1999 Transplantation pmid:10459544
Vu MD et al. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. 1997 Transplantation pmid:9422432
Deuse T et al. The interaction between FK778 and tacrolimus in the prevention of rat cardiac allograft rejection is dose dependent. 2004 Transplantation pmid:15084926
Ferraris JR et al. Conversion from cyclosporine A to tacrolimus in pediatric kidney transplant recipients with chronic rejection: changes in the immune responses. 2004 Transplantation pmid:15084930
Shapiro R et al. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. 1999 Transplantation pmid:10628763
Valdivia LA et al. Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. 1993 Transplantation pmid:7681230
Cox KL et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. 1995 Transplantation pmid:7533344
Sakr M et al. The protective effect of FK506 pretreatment against renal ischemia/reperfusion injury in rats. 1992 Transplantation pmid:1374948
Gerlach UA et al. Intragraft and Systemic Immune Parameters Discriminating Between Rejection and Long-Term Graft Function in a Preclinical Model of Intestinal Transplantation. 2017 Transplantation pmid:27607529
Selzner N et al. Conversion from cyclosporine to FK506 in adult liver transplant recipients: a combined North American and European experience. 2001 Transplantation pmid:11579301
Newell KA et al. Treatment with either anti-CD4 or anti-CD8 monoclonal antibodies blocks alphabeta T cell-mediated rejection of intestinal allografts in mice. 1997 Transplantation pmid:9381541
Petruzzo P et al. The International Registry on Hand and Composite Tissue Transplantation. 2010 Transplantation pmid:21052038
Yanchar NL et al. Tacrolimus (FK506)--its effects on intestinal glucose transport. 1996 Transplantation pmid:8610392
Reyes J et al. Expressive dysphasia possibly related to FK506 in two liver transplant recipients. 1990 Transplantation pmid:1701571
Rostaing L et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. 2005 Transplantation pmid:15818323
Grudé P et al. MDR1 gene expression in peripheral blood mononuclear cells after liver transplantation. 2002 Transplantation pmid:12085008
Xu X et al. FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506. 2002 Transplantation pmid:12085010
Pérgola PE et al. Kidney transplantation during the first trimester of pregnancy: immunosuppression with mycophenolate mofetil, tacrolimus, and prednisone. 2001 Transplantation pmid:11349738
Gruessner RW and Sharp HL Living-related intestinal transplantation: first report of a standardized surgical technique. 1997 Transplantation pmid:9415566
Gujadhur A et al. CMV sinusitis in a HIV-negative renal transplant recipient. 2014 Transplantation pmid:24827770
Moffatt SD et al. STAT 6 up-regulation by FK506 in the presence of interleukin-4. 2000 Transplantation pmid:10798785
Riegersperger M et al. Effect of conversion from ciclosporin to tacrolimus on endothelial progenitor cells in stable long-term kidney transplant recipients. 2013 Transplantation pmid:23594858
Woodle ES et al. FK506: inhibition of humoral mechanisms of hepatic allograft rejection. 1992 Transplantation pmid:1379749
Homma M et al. Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation. 2002 Transplantation pmid:11821750
Zaltzman JS A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers. 2010 Transplantation pmid:21166111
van Maarseveen EM et al. Pretransplantation pharmacokinetic curves of tacrolimus in HIV-infected patients on ritonavir-containing cART: a pilot study. 2013 Transplantation pmid:23250333
Chen H et al. Compromised kidney graft rejection response in Vervet monkeys after withdrawal of immunosuppressants tacrolimus and sirolimus. 2000 Transplantation pmid:10836361
Gouraud A et al. Follow-up of tacrolimus breastfed babies. 2012 Transplantation pmid:22996303
Bayés B et al. Adiponectin and risk of new-onset diabetes mellitus after kidney transplantation. 2004 Transplantation pmid:15257035
Deuse T et al. Significant reduction of acute cardiac allograft rejection by selective janus kinase-1/3 inhibition using R507 and R545. 2012 Transplantation pmid:22971540
Abu-Elmagd K et al. The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. 1991 Transplantation pmid:1713365
Glotz D et al. Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. 2010 Transplantation pmid:20386144
Miura Y et al. Factors increasing quantitative interstitial fibrosis from 0 hr to 1 year in living kidney transplant patients receiving tacrolimus. 2011 Transplantation pmid:21452412
Pascher A et al. Successful infliximab treatment of steroid and OKT3 refractory acute cellular rejection in two patients after intestinal transplantation. 2003 Transplantation pmid:12923454
Scheel AK et al. Severe neurotoxicity of tacrolimus (FK506) after renal transplantation: two case reports. 2001 Nov-Dec Transplant. Proc. pmid:11750573
Morris-Stiff G et al. Prospective randomized study comparing FK 506 (Prograft) and cyclosporine A (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases. 1998 Transplant. Proc. pmid:9636525
Kumai Y et al. Reversible Cerebral Vasoconstriction Syndrome After Heart Transplantation: A Case Report. 2017 Transplant. Proc. pmid:29198694
Barrera-Pulido L et al. Switching from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients with gastrointestinal complications. 2009 Jul-Aug Transplant. Proc. pmid:19715870
Burke GW et al. Cholesterol control: long-term benefit of pancreas-kidney transplantation with FK 506 immunosuppression. 1998 Transplant. Proc. pmid:9532153
Tsang WK et al. Efficacy and safety of mycophenolate mofetil in different dosages in Asian renal allograft recipients. 2000 Transplant. Proc. pmid:11119921
Gunji Y et al. Pathologic characteristics of vasculitis in renal transplant recipient dogs receiving immunosuppressive agents, FK 506, rapamycin, or RS-61443. 1993 Transplant. Proc. pmid:7679841
Jain AB et al. Pharmacokinetics of cyclosporine and nephrotoxicity in orthotopic liver transplant patients rescued with FK 506. 1991 Transplant. Proc. pmid:1721274
Namii Y et al. Tetrahydropyranyladriamycin with FK 506 combination therapy for hamster-to-rat-concordant xenotransplantation. 1996 Transplant. Proc. pmid:8623358
Ohara K et al. Toxicologic evaluation of FK 506. 1990 Transplant. Proc. pmid:1689910
Chan KL et al. Porcine small bowel transplantation with FK506 as a single immunosuppressant. 2001 Transplant. Proc. pmid:11406260
Platz KP et al. Indications for mycophenolate mofetil therapy in hepatitis C-patients undergoing liver transplantation. 1998 Transplant. Proc. pmid:9636596
Egawa H et al. Lymphoproliferative disorders in patients undergoing living-related liver transplantation. 1998 Transplant. Proc. pmid:9474982
Tellis V et al. No-load sirolimus with tacrolimus and steroids is safe and effective in renal transplantation. 2005 Transplant. Proc. pmid:15848571
Uchida H et al. Chronopharmacology of tacrolimus in rats: toxicity and efficacy in a mouse-to-rat intestinal transplant model and its pharmacokinetic profile. 1999 Transplant. Proc. pmid:10578276
Akbas SH et al. Evaluation of the new EMIT tacrolimus assay in kidney and liver transplant recipients. 2004 Jan-Feb Transplant. Proc. pmid:15013308
Choi SJ et al. Tacrolimus-induced apoptotic signal transduction pathway. 2008 Transplant. Proc. pmid:18929848
Hoshinaga K et al. Regimen of tacrolimus-based immunosuppression with basiliximab, mycophenolate mofetil, and low-dose steroid reduces acute rejection in kidney transplants. 2005 Transplant. Proc. pmid:15919457
Takaori K et al. Basic study on immunologic effects of cyclosporine and FK 506 for application to pancreatic transplantation. 1992 Transplant. Proc. pmid:1376531
Kuroki H and Ikuta Y Nerve regeneration of vascularized rat limb allograft and functional recovery of long-term graft survivals treated by short course of FK 506 or cyclosporine. 1995 Transplant. Proc. pmid:7533405
Shaw BW et al. FK 506 for rescue treatment of acute and chronic rejection in liver allograft recipients. 1991 Transplant. Proc. pmid:1721338
Junge G et al. Microchimerism in patients after orthotopic liver transplantation: a prognostic indicator? 2002 Transplant. Proc. pmid:12176475
Marqués E et al. Development of lymphoproliferative disease after liver transplantation. 2008 Transplant. Proc. pmid:19010169
Perego C et al. Orthotopic liver-small bowel transplantation in pigs: study of immunologic parameters during therapy with FK 506-based immunosuppressive regimens. 1996 Transplant. Proc. pmid:8907908
Hayakawa K et al. Involvement of clonal deletion in immunotolerance induction: tests of Tacrolimus administration in rat renal transplantation. 1994 Transplant. Proc. pmid:7520608
Fries D et al. Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation. 1991 Transplant. Proc. pmid:1721370
Jain AB et al. Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1703354
Moreno JM et al. Effectiveness and safety of mycophenolate mofetil as monotherapy in liver transplantation. 2003 Transplant. Proc. pmid:12962831
Shapiro R et al. A pilot trial of tacrolimus, sirolimus, and steroids in renal transplant recipients. 2002 Transplant. Proc. pmid:12176521
Nishimura Y et al. A trial to obtain donor-specific immunotolerance using a vascularized thymus allograft. 1998 Transplant. Proc. pmid:9838684
Damotte D et al. Morphologic features of large bowel biopsies in combined small and large bowel transplantations could predict clinical rejection. 1999 Feb-Mar Transplant. Proc. pmid:10083252
Zmonarski S et al. Expression of PBMC TLR4 in Renal Graft Recipients Who Experienced Delayed Graft Function Reflects Dynamic Balance Between Blood and Tissue Compartments and Helps Select a Problematic Patient. Transplant. Proc. pmid:30056893
Ota H et al. Intrathymic microchimerism predicts rejection response in allograft recipients. 1997 Feb-Mar Transplant. Proc. pmid:9123279
Kiuchi T et al. Experience of tacrolimus-based immunosuppression in living-related liver transplantation complicated with graft tuberculosis: interaction with rifampicin and side effects. 1996 Transplant. Proc. pmid:8962229
Arita S et al. Effect of FK 506 in experimental pancreas transplantation. 1995 Transplant. Proc. pmid:7536980
Bunnapradist S and Takemoto SK Controlling treatment allocation bias in a registry analysis when comparing calcineurin inhibitors. 2003 Transplant. Proc. pmid:14611971
Viebahn R et al. Hypoxic and reoxygenation injury in human and rat hepatocytes--influence of FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1721401
Sato K et al. Effectiveness of triple drug immunosuppression for pancreaticoduodenal allotransplantation in dogs. 1992 Transplant. Proc. pmid:1379753
Masaki Y et al. Microchimerism and rat small bowel transplantation combined with donor-type bone marrow cells. 1996 Transplant. Proc. pmid:8769154
Murphy MP and Morris RE Brequinar sodium effectively and potently suppresses allograft rejection in a heterotopic mouse heart transplant model. 1993 Transplant. Proc. pmid:7685955
Kobayashi C et al. Suppression of corneal graft rejection in rabbits by a new immunosuppressive agent, FK-506. 1989 Transplant. Proc. pmid:2468254
Salizzoni M et al. Tacrolimus-based dual therapy is as efficacious and safe as the conventional tacrolimus-based triple therapy in liver transplantation. 2001 Transplant. Proc. pmid:11377521
El Haggan W et al. One year evolution of bone mineral density in kidney transplant recipients receiving tacrolimus versus cyclosporine. 2002 Transplant. Proc. pmid:12176589
Ishibashi M et al. Experimental study of tacrolimus immunosuppression on the mode of administration: efficacy of constant intravenous infusion avoiding C(max). 2001 Feb-Mar Transplant. Proc. pmid:11266958
Cai W et al. Limited Sampling Strategy for Estimating Mycophenolic Acid Exposure on Day 7 Post-Transplant for Two Mycophenolate Mofetil Formulations Derived From 20 Chinese Renal Transplant Recipients. 2018 Transplant. Proc. pmid:29735215
Gibelli NE et al. Sirolimus in pediatric liver transplantation: a single-center experience. 2009 Transplant. Proc. pmid:19376384
Van Buren D et al. Impact of Sandimmune, Neoral, and Prograf on rejection incidence and renal function in primary liver transplant recipients. 1998 Transplant. Proc. pmid:9723299
Zhang J et al. Chemotherapy for De Novo Gastric Adenocarcinoma After Deceased Orthotopic Liver Transplantation: A Case Report. Transplant. Proc. pmid:28104131
Wu GD et al. FK 506 inhibits the development of transplant arteriosclerosis. 1991 Transplant. Proc. pmid:1721433
Todo S et al. Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. 1987 Transplant. Proc. pmid:2445076
Moreno M et al. Clinical management of tacrolimus drug interactions in renal transplant patients. 1999 Transplant. Proc. pmid:10500564
Tur MD et al. Apolipoprotein CIII is upregulated by anticalcineurins and rapamycin: implications in transplantation-induced dyslipidemia. 2000 Transplant. Proc. pmid:11134804
Hesse CJ et al. Evaluation of the new EMIT enzyme immunoassay for the determination of whole-blood tacrolimus concentrations in kidney, heart, and liver transplant recipients. 2002 Transplant. Proc. pmid:12431679
Preston R et al. FK 506 as primary immunosuppressive therapy in renal transplantation. 1998 Transplant. Proc. pmid:9636493
Guleria S et al. Tacrolimus (Pan Graf) as de novo therapy in renal transplant recipients in India. 2006 Transplant. Proc. pmid:16979989
Socci C et al. Pancreata from pediatric donors restore insulin independence in adult insulin-dependent diabetes mellitus recipients. 2010 Jul-Aug Transplant. Proc. pmid:20692410
Martins L et al. Cyclosporine versus tacrolimus in kidney transplantation: are there differences in nephrotoxicity? 2004 Transplant. Proc. pmid:15194300
Groth CG Immunosuppressive regimens of tomorrow. 1995 Transplant. Proc. pmid:8539797
Jiang H et al. Effect of FK 506 on heart allograft survival in highly sensitized recipient rats in comparison with cyclosporine. 1991 Transplant. Proc. pmid:1703702